



ASX Announcement | 08 December 2020
Althea Group Holdings (ASX:AGH)

Strong UK sales combine for record revenue in November

Investment Highlights:

- Althea continues its strong performance in the Australian and UK medicinal cannabis markets with unaudited revenue of \$847,499 in November 2020
- The average number of new patients and new prescribers in Australia per business day is at an all-time high
- Althea's UK operations continue to prosper with 48% month-on-month growth and unaudited revenue of \$110,378 recorded in November
- The Company is on track to deliver its biggest quarter to date following an excellent start to December

08 December 2020: **Australian pharmaceutical company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company')** is pleased to share the following market update on its Australian and UK operations, as the Company recorded its highest monthly revenue, number of new patients and new healthcare professionals (HCPs) per business day.

Average number of new patients and new HCPs at an all-time high

Althea Australia recorded its highest average number of new patients and new HCPs per business day in November, being 41.71 and 2.24, respectively.

Althea's Australian operations netted \$737,121 of unaudited revenue in November and the Company is seeing a strong rebound in sales in Victoria following a long COVID-19 lockdown. The Company expects its Australian growth to normalise in the coming months as the country's economy continues to recover.

Althea UK growth accelerating

Althea's UK operations continue to prosper with 48% month-on-month growth and unaudited revenue of \$110,378 recorded in November. Despite a nationwide COVID-19 lockdown commencing in early November and finishing on the 2nd of December, Althea continues to execute on its early mover advantage in the territory, with approximately half of Althea prescriptions generated from its wholly-owned subsidiary, MyAccess Clinics.

MyAccess Clinics is a leading healthcare provider in the United Kingdom, specialising in medicinal cannabis treatments and assessments.

Althea CEO Josh Fegan said: "I recently relocated permanently to London with my family to oversee the growth of the Althea brand in the UK and EU. With our market access strategy starting to resonate with UK prescribers and regulatory headwinds well and truly behind us, it is great to see our many months of hard work beginning to pay off. Our established Australian business continues to perform strongly, and we are looking forward to entering 2021 with fantastic momentum."

Althea Group Holdings Limited | ABN 78 626 966 943

A. Level 37, 360 Elizabeth Street, Melbourne, 3000, Victoria, Australia

E. info@althea.life

P. 1300 70 20 20

W. althea.life

Chart 1: Patient Growth in Australia as at 30 November 2020





Chart 2: HCP Growth in Australia as at 30 November 2020



-ENDS-



Authorised by: Robert Meissner, Company Secretary

For further information, please contact:

Althea

Josh Fegan

CEO & Managing Director

M: 1300 70 20 20

E: contact@althea.life

Media Enquiries

Dan Francome

Media Relations

P: +613 9650 5096

E: dfrancome@althea.life

Investor Relations

Jane Morgan

Investor Relations Partner

M: +61 405 555 618

E: jm@janemorganmanagement.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd (ASX:AGH) is a global pharmaceutical company and supplier of medicinal cannabis. Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia, United Kingdom and Germany, with plans to expand the brand into emerging markets across the world.

To learn more, please visit: www.althea.life

Althea Group Holdings Limited | ABN 78 626 966 943

A. Level 37, 360 Elizabeth Street, Melbourne, 3000, Victoria, Australia

E. info@althea.life

P. 1300 70 20 20

W. althea.life